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Zoltán Bánsághi1,4, Pál Novák Kaposi1, Gábor Lovas2,5, Gyöngyvér Szentmártoni1, György Várallyay3, Pál Bata1,
Ildikó Kalina1, Balázs Futácsi1 and Viktor Bérczi1*Abstract
We report the first European case of cerebral iodized lipid embolism post transcatheter arterial embolization
for hepatocellular carcinoma. Lipiodol emboli and corresponding multifocal brain ischemia were documented
with computed tomography (CT) and magnetic resonance (MR) in the acutely symptomatic patient.
Transcranial Doppler sonography with contrast indicated a right-to-left shunt, while on a follow-up CT scan
lipiodol embolization was detected in both lungs. Dilated pulmonary vessels and thick vascular channels were
seen in the vicinity of the right diaphragm suggestive of pulmonary arteriovenous shunt. The patient
symptoms regressed with supportive care alone, but he died 5 months later due to hepatic failure unrelated
to the procedure.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon solid malignancy [1]. Early stage HCC can be cura-
tively treated by liver resection, transplantation,
radiofrequency ablation (RFA), or percutaneous ethanol
injection (PEI) [2]. Unfortunately, in 60% to 70% of the
patients, the tumor has already progressed into an ad-
vanced stage at the time of diagnosis; thus, only pallia-
tive treatment could be offered. Transcatheter arterial
chemoembolization (TACE) has become the mainstay
therapy for HCC patients ineligible for surgery or tumor
ablation [2]. Transcatheter arterial embolization (TAE)
when Lipiodol is injected alone has been extensively
used and achieved comparable outcomes to TACE in
clinical trials [3]. The overall complication rate of
TACE/TAE is relatively low, 2.9%, but occasionally se-
vere side effects may develop leading to death or debili-
tating neurological deficits [2,4].* Correspondence: berczi@hotmail.com
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reproduction in any medium, provided the orPulmonary arteriovenous (AV) shunts are often her-
editary but can also be observed in a number of acquired
conditions including trauma and hepatic cirrhosis as
well as metastatic disease. In 95% of the cases, the pul-
monary AV shunt originates from a pulmonary artery,
and occasionally from a systemic artery [5]. In liver cir-
rhosis, multiplex pulmonary AV shunts can lead to hyp-
oxemia and peripheral cyanosis consistent with the
diagnosis of hepatopulmonary syndrome [6].
Previous reports have already suggested that pulmon-
ary AV shunts are the likely source of non-target embol-
ism post TAE/TACE [7]. In the present case, however,
pulmonary embolism, right-to-left shunting, and a pul-
monary AV shunt were simultaneously identified with
radiographic studies in agreement with a previously hy-
pothesized double shunt mechanism. According to our
knowledge the present case is also the first CLE reported
from a European country.
Case presentation
A 52-year-old man with a history of alcohol abuse
presented with right upper quadrant pain. On theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was identified. The tumor replaced most of the right
liver lobe and also expanded to the right diaphragm. Di-
lated vascular channels were detected inside the tumor
on color Doppler sonography (Figure 1A). However, no
spectral Doppler analysis was performed to identify po-
tential AV shunts. Fine needle aspiration biopsy (FNAB)
of the lesion verified the diagnosis of HCC. Subse-
quently, to reduce tumor size the patient was referred to
a TAE. Angiogram from a left brachial artery puncture
revealed that the liver mass was in part supplied by theFigure 1 The large right lobe HCC was embolized via the right
inferior phrenic artery. (A) Color Doppler sonography of the liver
revealed a hypervascular HCC, which almost completely replaced
the right lobe and extended to the diaphragm. (B) According to the
initial angiogram the tumor was in part supplied by both the right
inferior phrenic and the right hepatic arteries. Following selective
catheterization and TAE the feeding arteries were closed off with
gelatin sponge particles.right inferior phrenic artery (IPA) (Figure 1B) as well as
by the right hepatic artery branching off from the super-
ior mesenteric artery. The angiography did not detect
any apparent high flow shunts inside the tumor, al-
though small shunts might have gone undetected pre-
embolization. The feeding arteries were selectively
catheterized, embolization with 50 mL Lipiodol
(Guerbet, France) was performed, and the arterial lu-
mens were closed off with Spongostan (Johnson &
Johnson, NJ, USA) sponge particles. Thirty minutes later
the patient became agitated, disoriented, and unrespon-
sive, and started shivering. Cyanosis of both lower ex-
tremities was observed. A non-contrast computed
tomography (CT) scan obtained 2 h after the procedure
demonstrated hyperdense (60–65 HU) lipid droplets
scattered in the gyruses and the basal ganglia in both
hemispheres (Figure 2A). The electroencephalogram
(EEG) did not display abnormal activity compatible with
epileptic seizure or hepatic encephalopathy, however,
subcortical dysfunction was seen. TCD showed normal
flow in the circle of Willis. Following venous injection of
agitated saline solution, a RLS was detected by demon-
strating microbubbles in the right middle cerebral artery.
On the following day, diffusion-weighted magnetic res-
onance imaging (DW-MRI) of the brain showed dissemi-
nated areas of restricted diffusion indicative of recent
ischemic injury (Figure 2B). On the time-of-flight MR
angiography (TOF-MRA) all intracranial arteries were
patent. No intracranial bleeding or vascular shunt was
observed. On the second day post-embolization the pa-
tient became febrile, his status progressively deterio-
rated, myoclonus of the whole body and horizontal
nystagmus were detected. The patient was transferred to
the intensive care unit, where benzodiazepine sedation,
antibiotics, and ventilation therapy were started. On a
follow-up CT lipiodol embolization was found in both
lungs (Figure 3A), which was especially apparent in the
atelectatic basal areas. In addition, dilated vascular chan-
nels and a widened pulmonary vein (Figure 3B) could be
identified next to the right diaphragmatic surface sug-
gestive of a pulmonary AV shunt. Inside the liver mass,
extensive tumor necrosis was detected. The patient’s re-
spiratory and neurological status gradually improved in
the next 3 to 4 weeks. Unfortunately, the patient died
5 months later because of hepatic failure unrelated to the
procedure. The autopsy did not find macroscopic signs of
brain ischemia or evidence of a septal defect.Discussion
Cerebral iodized lipid embolism is a relatively rare com-
plication of TAE/TACE with <20 cases published in the
literature thus far [7,8]. To our best knowledge, ours is
the first case reported from a European country. This
Figure 2 Cerebral iodized lipid emboli were detected shortly after the embolization procedure. Two hours post TAE the patient
developed sudden neurological symptoms. (A) An emergent CT revealed scattered high attenuation spots in the gyruses and basal ganglia in
both hemispheres (arrows) indicative of iodized lipid embolization. (B) Diffusion-weighted MRI on the next day found disseminated acute
ischemic lesions (arrows) in corresponding locations.
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rates and greater incidence of HCC in other regions [1].
Also, due to the better surveillance and advancements in
patient management multiple embolizations can be
performed [2]. Therefore, increase in the number of
procedure-related adverse events can be expected. The
clinical and radiographic presentation of CLE is simi-
lar to lipid embolization. In most of the reported
cases, neurological deficits were mild or moderate in
severity and showed significant improvement or
complete remission within a few weeks [9]. Character-
istically, patients develop acute symptoms during or
shortly after the embolization procedure. Interestingly,
Wu et al. reported a delayed case of cerebral embol-
ism, which was observed 69 h following TACE [7].
Although most of the patients required supportive
care alone, massive lipid embolization post TACE can
occasionally result in a fatal outcome [4]. In our case,
ventilation support and intensive therapy were neces-
sary to stabilize the patient’s condition, in part because
of the pulmonary embolization and tumor necrosis
syndrome.
When CLE is suspected, radiographic studies can con-
firm non-target embolization by demonstrating emboliza-
tion material in the brain parenchyma [9]. Lipiodol itself is
a positive radiographic contrast agent. Therefore, on a
non-enhanced CT iodized lipid droplets show up as
scattered hyperattenuating dots in the basal ganglia, as
well as in the cerebral and cerebellar hemispheres. As in
the current case, MRI with diffusion-weighted imaging is
helpful to identify concomitant ischemic lesions, but fat
intensity from small lipid droplets could not be visualized.
Residual ischemic lesions are seldom seen on follow-upscans (4). EEG was essential to exclude other causes of the
abrupt neurological symptoms such as seizure or hepatic
encephalopathy.
The exact embolization route often remains undeter-
mined in the reported CLE cases. Our case is excep-
tional since we could also demonstrate that a pulmonary
AV shunt was the likely source of the cerebral emboli. In
the vicinity of the right diaphragmatic surface, dilated
vascular channels and a widened pulmonary vein could
be identified suggestive of a pulmonary shunt. This pul-
monary AV shunt most likely was supplied by a segmen-
tal pulmonary artery branch. Consistently, right-to-left
shunting was documented on the saline contrast TDS.
Pulmonary AV shunts may develop on the tumor surface
or at pleural adhesions. CLE is often described in HCC
patients with diaphragmatic involvement or large right
lobe tumors. In addition pulmonary embolism may have
facilitated the opening of pre-existent pulmonary AV
shunts by increasing the pulmonary arterial pressure [7].
Similar to our patient, at least six CLE cases have
been reported, where HCC was in part supplied by
the right IPA [4,7,8]. Shunting between the IPA and
the pulmonary venous systems was not detected; thus,
direct embolization is an unlikely source of brain
emboli. Indirect evidence from extensive lipiodol
embolization in both lungs indicates that simulta-
neous systemic and pulmonary shunts lead to non-
target embolization. On color Doppler sonography,
dilated vascular channels were seen inside the tumor.
Although the initial angiogram could not demonstrate
apparent AV shunting, a low volume shunt might
have gone undetected pre-embolization. It is less
likely but also possible that embolization altered the
Figure 3 Extensive pulmonary embolization and dilated
pulmonary vessels could be observed post embolization. (A) A
follow-up CT performed 3 days post TAE showed extensive lipiodol
embolization (arrowheads) in both lungs well visible in the
atelectatic basal segments. (B) In the vicinity of the right
diaphragmatic surface, widened vascular spaces (arrowheads) and a
thick pulmonary vein (arrow) could be identified, suggestive of a
pulmonary AV shunt.
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tumor.
Additional risk factors of CLE can be determined by
comparing previously reported cases with the present
one. Based on the literature the volume of lipiodol ap-
pears to correlate directly with the duration of post
embolization recovery, and the complication rate in-
creases when >20 mL is injected [10]. Due to the large
size of the tumor, we used 50 mL lipiodol for the
embolization, twice the standard dose. This could havesignificantly contributed to the extensive non-target
embolization in the current case. In their review Wu et al.
reported that nine out of 12 CLE cases occurred after re-
peated embolization sessions [7]. Prior embolizations of
the feeding arteries could have resulted in extensive ne-
crosis and collateralization of the vascular supply; thus,
high flow AVS may have developed in the previously
treated areas. No prior embolization was performed in
our case. A patent foramen ovale (PFO) has a 10% to 20%
prevalence in the adult population. This makes PFO a po-
tential embolization pathway in CLE patients. Indeed,
there are well documented CLE cases, when a PFO was
verified with trans-esophageal echocardiography [8]. Still,
in most of the CLE patients there is no evidence of intra-
cardiac shunting [8]. The autopsy could not identify an
ISD in the present case either.
Conclusions
In summary CLE is a relatively rare, but well-
documented complication of TAE in HCC patients.
Cerebral embolization could be traced back to a pul-
monary AV shunt in the current case, and it may have
been a potential embolization source in other published
cases, as well. Thus, in patients with advanced tumors
and high risk of CLE a less aggressive embolization strat-
egy or alternative treatment methods should be consid-
ered. If CLE still occurs, neurological symptoms may
regress spontaneously, and most patients require symp-
tomatic management only.
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